Bionano Genomics, Inc. BNGO PHARMA
Company Overview
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for solutions for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Why Investors Should Care
Revenue has grown at a 14.7% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.21.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $28.51M (-7.4% YoY); net profit $-26.39M.
- Trailing 12 Months Year-on-year growth — revenue +21.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 14.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 14.72% |
| 1 Year: | 21.40% |
Stock Price Performance
| 1 Year: | -62.96% |
| 6 Months: | +7.14% |
| 3 Months: | +2.56% |
| 1 Month: | +3.45% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)51.09 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 14.7% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 75.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BNGO Bionano Genomics, Inc. PHARMA | 1.20 | -0.40 | $14.13M | 0.00% | -65.83% | -83.56% | 14.72% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 2.74M | - | 1.77M | 3.39M | 2.83M | 4.01M | 1.85M | 2.17M | 3.31M | 2.79M | 1.14M | 1.18M | 2.20M | 3.17M | 3.86M | 4.66M | 5.70M | 6.67M | 7.22M | 7.42M | 8.66M | 9.32M | 8.77M | 7.77M | 6.07M | 6.46M | 6.73M | 7.37M | 6.69M | 8.17M |
| Operating Income | - | - | -5.03M | - | -4.34M | -4.01M | -5.97M | - | -6.18M | -6.84M | -5.68M | - | -9.76M | -7.43M | -10.23M | -11.16M | -16.48M | -20.68M | -29.94M | -32.08M | -32.15M | -37.84M | -39.24M | -113.21M | -31.12M | -17.02M | -43.90M | -8.46M | -7.80M | -8.54M | -7.90M | -7.22M |
| Net Income | 5.69M | 6.67M | 5.09M | 5.92M | -3.85M | -3.31M | -4.93M | -6.41M | -7.85M | -7.67M | -6.40M | -7.90M | -10.51M | -8.07M | -10.79M | -9.95M | -18.79M | -20.75M | -29.95M | -32.16M | -31.81M | -37.12M | -38.91M | -112.57M | -31.42M | -16.22M | -44.25M | -3.10M | -6.86M | -8.50M | -8.30M | -7.42M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.09 | -0.08 | -0.04 | -0.07 | -0.07 | -0.11 | -1.13 | -1.10 | -1.23 | -1.24 | -3.22 | -35.75 | -14.41 | -30.92 | -1.15 | -1.99 | -1.59 | -0.76 | -0.64 |
| R&D Expense | - | - | 2.97M | - | 2.37M | 2.10M | 2.51M | - | 2.10M | 2.41M | 2.17M | - | 2.67M | 2.40M | 2.30M | 2.68M | 4.09M | 6.50M | 10.53M | 11.77M | 12.74M | 13.94M | 14.61M | 13.79M | 9.78M | 6.83M | 4.72M | 2.37M | 2.93M | 2.84M | 3.14M | 2.99M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.51M | 12.00M | 10.13M | 8.50M | 17.98M | 27.80M | 36.12M | 30.78M | 28.51M |
| Operating Income | -23.22M | -20.42M | -25.87M | -38.55M | -77.10M | -131.70M | -215.25M | -103.98M | -33.34M |
| Net Income | -23.37M | -18.50M | -29.82M | -41.11M | -72.44M | -132.60M | -232.49M | -112.02M | -26.39M |
| Diluted EPS | - | - | - | - | -0.26 | -4.58 | -408.60 | -88.13 | -4.85 |
| R&D Expense | 12.01M | 9.48M | 9.08M | 10.26M | 22.48M | 49.05M | 54.03M | 24.80M | 11.37M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 10.15M | 24.80M | 30.21M | 60.45M | 377.10M | 307.50M | 214.40M | 76.67M | 73.58M |
| Total Equity | -27.26M | -50.23M | 10.14M | 3.61M | 35.08M | 337.12M | 249.40M | 96.16M | 35.38M | 44.42M |
| Cash & Equivalents | - | 1.02M | 16.52M | 17.31M | 38.45M | 24.57M | 5.09M | 17.95M | 9.17M | 2.99M |
| Long Term Debt | - | 0 | 9.03M | 0 | 16.32M | 0 | - | - | - | - |
| Total Liabilities | - | 17.36M | 14.67M | 26.59M | 25.37M | 39.98M | 58.10M | 118.25M | 41.30M | 29.16M |
| Current Liabilities | - | 16.65M | 4.52M | 26.37M | 8.95M | 21.84M | 35.88M | 100.03M | 37.34M | 22.94M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -20.82M | -19.94M | -29.53M | -38.31M | -71.93M | -124.82M | -125.18M | -68.92M | -16.34M |
| Investing Cash Flow | -1.02M | -331.72K | -61.06K | -2.45M | -278.06M | 82.77M | 24.16M | 73.84M | -12.75M |
| Financing Cash Flow | 17.61M | 35.78M | 30.38M | 61.90M | 336.11M | 23.01M | 113.81M | -13.69M | 24.04M |
| Capital Expenditure | -1.02M | -331.72K | -61.06K | -0 | - | - | - | - | - |
| Free Cash Flow | -21.84M | -20.28M | -29.59M | -38.31M | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -244.3% | -170.1% | -255.4% | -453.4% | -428.8% | -473.7% | -596.0% | -337.9% | -116.9% |
| Net Margin % | -245.8% | -154.1% | -294.3% | -483.4% | -402.8% | -476.9% | -643.7% | -364.0% | -92.6% |
| ROE % | 46.5% | -182.5% | -825.2% | -117.2% | -21.5% | -53.2% | -241.8% | -316.7% | -59.4% |
| ROCE % | 356.8% | -100.7% | -673.7% | -74.8% | -21.7% | -48.5% | -188.2% | -264.4% | -65.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | GSA Capital Partners LLP | 1.28% | 150.28K | $259.99K |
| 2 | Carret Asset Management, LLC | 1.06% | 125.00K | $216.25K |
| 3 | Geode Capital Management, LLC | 0.76% | 89.99K | $155.69K |
| 4 | Vanguard Capital Management LLC | 0.70% | 82.39K | $142.53K |
| 5 | Vanguard Fiduciary Trust Co | 0.44% | 51.58K | $89.23K |
| 6 | Renaissance Technologies, LLC | 0.43% | 51.10K | $88.40K |
| 7 | Jane Street Group, LLC | 0.30% | 35.73K | $61.81K |
| 8 | Prudential Financial, Inc. | 0.27% | 31.60K | $54.67K |
| 9 | Northern Trust Corporation | 0.21% | 24.56K | $42.49K |
| 10 | Xtx Topco Ltd | 0.14% | 16.30K | $28.19K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BNGO
Bionano Genomics (BNGO) Upgraded to Buy: What Does It Mean for the Stock? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQbFl4VzE3WkVUY1ZzUnZFV0ZrdnlDVUdoaXZLZEhOb2V6UVdSVjVwRDZYYTRmdUJKb1Y0SW9OaW16dm13ZThteGJaWjJpUEJSMkZSSnBhRTgyOGstdHlwbFhvYUl2eDRQYWhJV2lBUW4xQ0ZxaU9xZl9Sa3JEU2d0dGY4a3JObnhGV0pQX3…
Bionano Genomics (BNGO) CSO reports holding 63 shares - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxQM1JOX0t4d1BOVXlLZW1NOUFoaTlwVGFBYlpEYjF4Y21EdVJpVm1BTWJBaDA2M0Z4Wm5vV3lFb2RYcEJUNU5yTDJhWVo1aUdJc1hDdmZiaW1SaV9CZG1kbkZaRG1RanNBNllhekJCYzVqS05TWFNsMkIzZXhKa3hkcG5HQkdRMUx1LWlxNH…
BNGO - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE41Z1lJdkU3Z2JOT1JWdnNQS2JMd3hEbndlWloyY040V3ZHUV9tc29xQkJBYUZRNmNiTU1uSERuRDc5aXRtaFE?oc=5" target="_blank">BNGO</a> <font color="#6f6f6f">Finviz</font>…
Market Cool On Bionano Genomics, Inc.'s (NASDAQ:BNGO) Revenues - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxQSmhxWFc4QXNvSDBWOWNyakoweDhTZXNIUWhZbUZtSWFtaDZwaU9TeGN2QXpoYUhJb01VcndORDB1TS1qRkZpZ3ZYZGhYQmVHQjdld0NKZldYSjRvMXd1UFItVzNSUU1lX0t2X21tUGx3VTZWdmdXdFFweVl6eElPUHpTMnk3bDZBbnJMaz…
Why Fast-paced Mover Bionano Genomics (BNGO) Is a Great Choice for Value Investors - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxPVUI5Y2pzeWMyRUpEOUFTWGFnYXQ0NnVBZG40bGs5SlJpelZ2TkR2U0Y5MzNsdkJHekRKMWhPbGpONVVjUkZUc1drZGpnZE12Slo0RTFSZWp6bnJobE1XZFhmVW9Za2xkaUpoemV1RGdBYUUyUkp3NDRmS1RCc2dhOUZ1WEpvU0xQR1NTZD…
5 Biotech Stocks We Like in 2026. And 5 We Don’t - Nanalyze
<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxOU1ZTSW1TdXNaOXJITWJ0MTlHOXdDRkVwR19zaTl2MV82SWNWeGxzb29LeEhPZ2hqYlhNVW5fYnpGVnY4c1VRZ1Q1VnVvNVcyQ3h1YnBmTUxLdkZ2V25FX092QVhNVHlpYU91ZF9Ta2QtcjMwR0pLU2d1VTJFZkhjTXZtY29xZw?oc=5" t…
BNGO — Frequently Asked Questions
What is the current share price of Bionano Genomics, Inc. (BNGO)?
As of 2026-09-19 21:16 PDT, Bionano Genomics, Inc. (BNGO) trades at $1.20 on NasdaqCM. Its 52-week range is $1.06 to $4.92.
What is the market capitalisation of BNGO?
Bionano Genomics, Inc. (BNGO) has a market capitalisation of $14.13M on NasdaqCM.
What is the P/E ratio of BNGO?
BNGO trades at a trailing price-to-earnings (P/E) ratio of -0.40. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.44.
What is the return on equity (ROE) of BNGO?
BNGO has a return on equity (ROE) of -83.56%. Its return on capital employed (ROCE) is -65.83%.
Is BNGO a good stock to buy?
This page provides a data-driven analysis of Bionano Genomics, Inc. (BNGO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.